肿瘤防治研究2024，Vol.51Issue(8)：690-696,7.DOI:10.3971/j.issn.1000-8578.2024.24.0108
恶性胸膜间皮瘤化疗抵抗机制研究进展
Research Progress on Molecular Mechanism Underlying Chemotherapy Resistance of Malignant Pleural Mesothelioma
摘要
Abstract
Malignant pleural mesothelioma(MPM)is a rare,highly aggressive,and lethal tumor with poor prognosis.Its survival period ranges from four months to one year,and the 5-year survival rate is only about 10%.MPM is highly resistant to chemotherapy,and conventional treatments such as cisplatin combined with pemetrexed or raltitrexed only have a certain effect in about 20%of patients.In recent years,with the continuous in-depth understanding of the genetic variation characteristics of MPM,some progress has been made in the molecular mechanism underlying the chemotherapy resistance of MPM.This article will summarize the research progress of the molecular mechanism underlying the chemotherapy resistance of MPM,including BAP1 gene mutation,microRNA,MTA1-mediated DNA damage repair pathway,GITR-GITRL pathway,TGFa pathway,tumor stem cell,EGFR,and PTEN.The aim of this work is to provide a reference for exploring new therapeutic targets and combined treatment options for MPM.关键词
恶性胸膜间皮瘤/化疗抵抗/分子机制Key words
Malignant pleural mesothelioma/Chemotherapy resistance/Molecular mechanism分类
医药卫生引用本文复制引用
张利,于杰,陈瑜,罗小迪,汪继翠,涂东..恶性胸膜间皮瘤化疗抵抗机制研究进展[J].肿瘤防治研究,2024,51(8):690-696,7.基金项目
Science and Technology Plan Project of Yunnan Province Science and Technology Department(No.202101AY070001-303)云南省科技厅科技计划项目(202101AY070001-303) （No.202101AY070001-303）
